Nifty
:
10710.80
Sensex
:
36093.47
-129.85 (-1.20%)
-470.41 (-1.29%)
Nifty
Sensex
:
:
10710.80
36093.47
-129.85 (-1.20%)
-470.41 (-1.29%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs

Rating :
50/99

BSE: 532296 | NSE: GLENMARK

NSE BSE
362.85
18-Sep-2019
  • Open
  • High
  • Low
  • Previous Close
  •  370.90
  •  371.90
  •  360.30
  •  370.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1099344
  •  4010.37
  •  705.90
  •  353.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 10,234.24
  • 12.77
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 13,745.14
  • 0.55%
  • 1.79

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.58%
  • 3.12%
  • 9.35%
  • FII
  • DII
  • Others
  • 2.62%
  • 4.88%
  • 33.45%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.80
  • 8.11
  • 2.81

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.85
  • 5.48
  • -4.88

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.04
  • 34.58
  • -5.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.23
  • 26.28
  • 19.32

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.26
  • 5.62
  • 3.83

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.21
  • 15.32
  • 12.12

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Net Sales
2,322.88
2,165.62
7.26%
2,563.47
2,279.82
12.44%
2,555.05
2,203.66
15.95%
2,581.33
2,256.59
14.39%
Expenses
1,980.97
1,818.73
8.92%
2,199.34
1,952.98
12.61%
2,120.37
1,880.97
12.73%
2,141.23
1,868.19
14.62%
EBITDA
341.91
346.88
-1.43%
364.13
326.83
11.41%
434.68
322.69
34.71%
440.11
388.40
13.31%
EBIDTM
14.72%
16.02%
14.20%
14.34%
17.01%
14.64%
17.05%
17.21%
Other Income
1.67
138.22
-98.79%
39.06
69.55
-43.84%
-109.02
-23.16
-
139.88
29.73
370.50%
Interest
93.02
79.01
17.73%
81.91
74.39
10.11%
88.53
70.47
25.63%
85.13
69.84
21.89%
Depreciation
90.73
79.38
14.30%
80.97
73.53
10.12%
83.10
75.38
10.24%
82.45
75.23
9.60%
PBT
159.83
326.70
-51.08%
240.31
248.47
-3.28%
154.03
153.67
0.23%
579.59
273.05
112.27%
Tax
50.55
93.71
-46.06%
78.65
96.84
-18.78%
37.69
48.93
-22.97%
165.59
58.93
180.99%
PAT
109.28
232.99
-53.10%
161.66
151.63
6.61%
116.34
104.74
11.08%
414.00
214.12
93.35%
PATM
4.70%
10.76%
6.31%
6.65%
4.55%
4.75%
16.04%
9.49%
EPS
3.87
8.26
-53.15%
5.73
5.37
6.70%
4.12
3.71
11.05%
14.67
7.59
93.28%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
10,022.73
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
2,949.07
2,480.46
Net Sales Growth
12.54%
8.72%
-0.05%
20.07%
13.18%
12.38%
19.64%
23.59%
36.34%
18.89%
 
Cost Of Goods Sold
3,413.65
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
951.07
784.28
Gross Profit
6,609.08
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
1,998.00
1,696.18
GP Margin
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
67.75%
68.38%
Total Expenditure
8,441.91
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
2,356.82
1,860.89
Power & Fuel Cost
-
165.25
137.47
127.02
120.47
109.11
93.50
80.13
0.00
0.00
31.86
% Of Sales
-
1.68%
1.51%
1.40%
1.59%
1.63%
1.57%
1.61%
0%
0%
1.28%
Employee Cost
-
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
510.17
289.95
% Of Sales
-
20.84%
20.63%
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
17.30%
11.69%
Manufacturing Exp.
-
725.16
648.59
546.75
956.59
1,323.66
336.59
272.53
54.40
40.76
142.80
% Of Sales
-
7.35%
7.15%
6.02%
12.65%
19.81%
5.66%
5.48%
1.35%
1.38%
5.76%
General & Admin Exp.
-
625.20
805.17
1,022.89
491.20
253.29
859.67
678.94
1,331.99
854.82
268.51
% Of Sales
-
6.34%
8.87%
11.27%
6.50%
3.79%
14.46%
13.66%
33.13%
28.99%
10.83%
Selling & Distn. Exp.
-
1,125.08
996.99
1,064.70
892.67
991.23
524.25
521.00
0.00
0.00
310.32
% Of Sales
-
11.40%
10.99%
11.73%
11.81%
14.84%
8.82%
10.48%
0%
0%
12.51%
Miscellaneous Exp.
-
299.19
35.66
88.52
38.82
38.48
228.40
33.61
0.00
0.00
310.32
% Of Sales
-
3.03%
0.39%
0.97%
0.51%
0.58%
3.84%
0.68%
0%
0%
1.34%
EBITDA
1,580.83
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
592.25
619.57
EBITDA Margin
15.77%
16.07%
17.80%
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
20.08%
24.98%
Other Income
71.59
208.14
91.40
37.37
20.00
6.88
11.48
10.75
18.17
144.41
50.45
Interest
348.59
334.58
285.57
237.32
178.88
190.15
188.59
160.01
146.57
160.46
165.50
Depreciation
337.25
325.90
301.88
264.37
234.28
300.41
216.79
127.01
97.88
94.68
120.61
PBT
1,133.76
1,133.45
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
488.09
481.54
383.90
Tax
332.48
375.64
315.46
382.68
300.94
334.07
151.27
110.72
23.78
23.70
52.87
Tax Rate
29.33%
28.88%
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
4.92%
13.77%
PAT
801.28
924.98
803.78
1,108.80
743.23
209.54
542.27
620.03
460.35
453.20
324.47
PAT before Minority Interest
801.23
924.99
803.87
1,108.75
743.04
209.47
545.60
628.29
464.31
457.83
331.03
Minority Interest
-0.05
-0.01
-0.09
0.05
0.19
0.07
-3.33
-8.26
-3.96
-4.63
-6.56
PAT Margin
7.99%
9.38%
8.86%
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
15.37%
13.08%
PAT Growth
13.90%
15.08%
-27.51%
49.19%
254.70%
-61.36%
-12.54%
34.69%
1.58%
39.67%
 
Unadjusted EPS
28.39
32.78
28.49
39.29
26.47
7.72
20.01
22.91
17.03
16.78
12.40

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
2,037.24
2,355.23
Share Capital
28.22
28.22
28.22
28.22
27.13
27.12
27.09
27.05
27.03
26.98
Total Reserves
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
2,010.21
2,328.25
Non-Current Liabilities
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
519.01
1,940.41
Secured Loans
0.00
0.00
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
617.07
241.41
Unsecured Loans
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
0.00
1,627.98
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
14.58
6.90
0.00
Current Liabilities
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
2,259.06
518.62
Trade Payables
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
1,036.94
788.83
657.41
379.27
Other Current Liabilities
1,013.21
690.60
509.32
1,137.01
1,264.30
973.31
763.41
414.83
109.80
119.38
Short Term Borrowings
303.02
295.04
187.19
787.42
347.60
353.32
367.82
687.46
1,480.23
0.00
Short Term Provisions
484.11
432.46
262.95
134.03
216.78
259.95
33.22
10.63
11.62
19.97
Total Liabilities
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
4,842.01
4,827.27
Net Block
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
2,066.62
1,787.31
Gross Block
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
2,383.39
2,175.54
Accumulated Depreciation
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
316.77
388.23
Non Current Assets
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
2,243.24
2,406.20
Capital Work in Progress
1,398.94
1,121.87
708.11
542.79
477.13
206.24
422.31
248.33
145.70
600.77
Non Current Investment
29.66
14.66
15.69
17.20
17.12
0.00
0.00
0.00
0.00
18.12
Long Term Loans & Adv.
109.57
119.78
98.94
69.99
468.16
33.39
36.52
0.00
0.00
0.00
Other Non Current Assets
0.59
0.56
0.13
0.16
0.27
20.33
22.00
33.23
30.92
0.00
Current Assets
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
2,598.77
2,421.07
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
807.01
708.46
Sundry Debtors
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
1,130.81
1,078.28
Cash & Bank
937.76
1,234.69
1,057.66
857.12
775.88
800.67
607.31
321.92
195.83
107.02
Other Current Assets
1,312.40
810.78
683.39
391.88
774.38
872.81
635.91
593.95
465.11
527.31
Short Term Loans & Adv.
547.18
580.83
590.22
594.89
742.94
768.44
540.03
518.90
322.39
527.31
Net Current Assets
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
339.71
1,902.45
Total Assets
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00
4,842.01
4,827.27

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,324.17
1,648.05
657.43
344.85
481.68
853.73
647.93
804.39
930.58
352.40
PBT
1,300.63
1,119.33
1,491.43
1,043.98
543.54
696.88
739.00
488.09
481.55
383.90
Adjustment
329.83
571.28
726.56
391.03
522.76
709.78
342.45
484.05
189.65
265.26
Changes in Working Capital
136.34
309.06
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
353.13
-209.36
Cash after chg. in Working capital
1,766.81
1,999.67
1,356.48
823.05
799.49
1,116.58
812.96
937.35
1,024.34
439.80
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-442.63
-351.61
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
-93.75
-87.40
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-698.99
-1,013.34
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
-367.27
-386.91
Net Fixed Assets
455.14
-362.24
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
-40.77
-52.58
Net Investments
-56.07
-1,345.98
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
-48.33
-755.29
Others
-1,098.06
694.88
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
-278.17
420.96
Cash from Financing Activity
-738.74
-468.50
543.15
698.60
199.22
-98.02
195.24
-361.39
-435.61
70.05
Net Cash Inflow / Outflow
-113.56
166.21
488.24
163.27
140.86
387.61
379.11
165.21
127.70
35.54
Opening Cash & Equivalents
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
103.58
71.48
Closing Cash & Equivalent
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
107.02

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
198.27
182.62
159.16
128.59
65.74
109.99
102.01
88.77
75.38
87.28
ROA
7.98%
7.40%
11.33%
8.52%
2.58%
7.51%
10.40%
9.01%
9.47%
7.33%
ROE
17.21%
16.67%
27.31%
27.46%
8.79%
18.99%
24.33%
20.92%
20.85%
16.75%
ROCE
16.47%
14.77%
20.54%
18.53%
12.40%
15.04%
17.67%
14.44%
15.34%
13.88%
Fixed Asset Turnover
1.66
1.80
2.03
1.96
1.90
1.83
1.79
1.60
1.29
1.25
Receivable days
83.73
94.95
97.29
119.39
125.97
115.37
104.99
107.78
136.71
148.42
Inventory Days
79.22
83.59
73.65
67.68
59.42
53.99
59.39
72.38
93.78
97.70
Payable days
97.43
96.28
101.59
117.03
95.22
83.15
68.48
108.47
106.73
68.48
Cash Conversion Cycle
65.53
82.26
69.35
70.04
90.17
86.21
95.91
71.69
123.76
177.63
Total Debt/Equity
0.80
0.90
1.05
1.10
2.13
1.10
1.00
0.93
1.03
0.79
Interest Cover
4.89
4.92
7.28
6.84
3.86
4.70
5.62
4.33
4.00
3.32

Annual Reports:

FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011
FY 2010

News Update:


  • Glenmark receives Orphan Drug Designation for GBR 1342
    17th Sep 2019, 09:25 AM

    The candidate is one of five clinical-stage assets in the pipeline of Glenmark’s new innovation company

    Read More
  • Glenmark Pharma’s arm gets USFDA’s final nod for Clobetasol Propionate Foam
    10th Sep 2019, 09:31 AM

    The Olux-E Foam, 0.05% market achieved annual sales of approximately $11.1 million

    Read More
  • Glenmark initiates process of reorganising itself into three different entities
    5th Sep 2019, 11:44 AM

    The company expects the process to be completed in the current fiscal year

    Read More
  • Glenmark Pharma’s arm receives USFDA’s approval for Pimecrolimus Cream
    30th Aug 2019, 09:17 AM

    The Elidel Cream, 1% market achieved annual sales of approximately $198.8 million

    Read More
  • Glenmark Pharma's arm receives USFDA’s approval for Fulvestrant Injection
    23rd Aug 2019, 09:15 AM

    The Faslodex Injection, 250 mg/5 mL (50 mg/mL) market achieved annual sales of approximately $549.9 million

    Read More
  • Glenmark Pharma gets nod for combination of Remogliflozin and Metformin
    19th Aug 2019, 12:22 PM

    The company will commercialize the combination under the brand names ‘Remo-M’ and ‘Remozen-M’

    Read More
  • Glenmark Pharmaceuticals reports 53% fall in Q1 consolidated net profit
    14th Aug 2019, 10:55 AM

    Total consolidated income of the company increased marginally by 0.90% at Rs 2,324.55 crore for Q1FY20

    Read More
  • Glenmark Pharma - Quarterly Results
    13th Aug 2019, 18:50 PM

    Read More
  • Glenmark Pharma signs licensing agreement with Torrent Pharma
    11th Jul 2019, 09:13 AM

    The company will receive an upfront payment, license fees and royalties for the non-exclusive sub-license rights from Torrent

    Read More
  • Glenmark’s arm receives USFDA’s final approval for Ranolazine Extended-Release Tablets
    9th Jul 2019, 09:10 AM

    Ranexa Extended Release Tablets, 500 mg and 1,000 mg market achieved annual sales of approximately $929.0 million

    Read More
  • Glenmark Pharma's arm receives USFDA’s approval for Ezetimibe and Simvastatin Tablets
    28th Jun 2019, 09:19 AM

    The Vytorin Tablets market achieved annual sales of approximately $92.4 million

    Read More
  • Glenmark Pharma receives complete response letter from USFDA for Ryaltris
    24th Jun 2019, 14:36 PM

    The CRL does not specify any deficiencies with the clinical data supporting the New Drug Application for Ryaltris

    Read More
  • Glenmark Pharma’s arm signs partnership agreement with Novartis Biosciences
    24th Jun 2019, 09:08 AM

    The products involved in the agreement are Seebri, Onbrize and Ultibro

    Read More
  • Glenmark Pharmaceuticals’ arm receives tentative ANDA approval for Clindamycin Phosphate Foam
    20th Jun 2019, 09:15 AM

    The company continues to identify and explore external development partnerships

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.